vs
Side-by-side financial comparison of Pelthos Therapeutics Inc. (PTHS) and Hyperliquid Strategies Inc (PURR). Click either name above to swap in a different company.
Hyperliquid Strategies Inc is the larger business by last-quarter revenue ($500.0K vs $294.0K, roughly 1.7× Pelthos Therapeutics Inc.). Pelthos Therapeutics Inc. runs the higher net margin — -5523.1% vs -60892.6%, a 55369.5% gap on every dollar of revenue.
Pelthos Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare metabolic and endocrine diseases with significant unmet medical needs. It operates primarily across North America and Europe, with a pipeline of novel drug candidates addressing underserved patient populations.
PTHS vs PURR — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $294.0K | $500.0K |
| Net Profit | $-16.2M | $-304.5M |
| Gross Margin | -687.8% | — |
| Operating Margin | -5225.2% | -57509.2% |
| Net Margin | -5523.1% | -60892.6% |
| Revenue YoY | — | — |
| Net Profit YoY | -858.0% | — |
| EPS (diluted) | $-5.30 | $-7.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $500.0K | ||
| Q3 25 | $294.0K | — |
| Q4 25 | — | $-304.5M | ||
| Q3 25 | $-16.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | -687.8% | — |
| Q4 25 | — | -57509.2% | ||
| Q3 25 | -5225.2% | — |
| Q4 25 | — | -60892.6% | ||
| Q3 25 | -5523.1% | — |
| Q4 25 | — | $-7.43 | ||
| Q3 25 | $-5.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.2M | $281.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.3M | $589.8M |
| Total Assets | $126.4M | $616.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $281.9M | ||
| Q3 25 | $14.2M | — |
| Q4 25 | — | $589.8M | ||
| Q3 25 | $58.3M | — |
| Q4 25 | — | $616.6M | ||
| Q3 25 | $126.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $-15.3M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
